StemRIM Inc. Logo

StemRIM Inc.

Develops regenerative medicine that uses the body's own stem cells for tissue repair.

4599 | T

Overview

Corporate Details

ISIN(s):
JP3399690001
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ7丁目7番15号

Description

StemRIM Inc. is a biotechnology company developing a next-generation category of regenerative medicine called “Regeneration-Inducing Medicine™”. This innovative approach aims to treat intractable diseases and injuries by maximizing the body's innate tissue repair capabilities. The core mechanism of action involves mobilizing a patient's own endogenous stem cells to damaged tissues to induce functional regeneration, a method distinct from conventional cell-therapy. The company's research and development focuses on creating new drugs based on this novel mechanism, with applications including gene therapy for rare skin diseases such as dystrophic epidermolysis bullosa.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-07-26 09:08
臨時報告書
Japanese 22.1 KB
2023-06-14 08:51
確認書
Japanese 8.7 KB
2023-06-14 08:50
四半期報告書-第18期第3四半期(2023/02/01-2023/04/30)
Japanese 210.8 KB
2023-03-09 02:26
確認書
Japanese 8.7 KB
2023-03-09 02:16
四半期報告書-第18期第2四半期(2022/11/01-2023/01/31)
Japanese 220.1 KB
2022-12-15 02:23
確認書
Japanese 8.7 KB
2022-12-15 02:22
四半期報告書-第18期第1四半期(令和4年8月1日-令和4年10月31日)
Japanese 196.0 KB
2022-10-27 09:00
内部統制報告書-第17期(令和3年8月1日-令和4年7月31日)
Japanese 22.5 KB
2022-10-27 08:59
確認書
Japanese 8.8 KB
2022-10-27 08:58
有価証券報告書-第17期(令和3年8月1日-令和4年7月31日)
Japanese 3.0 MB
2022-06-10 04:39
四半期報告書-第17期第3四半期(令和4年2月1日-令和4年4月30日)
Japanese 192.2 KB
2022-03-11 04:54
四半期報告書-第17期第2四半期(令和3年11月1日-令和4年1月31日)
Japanese 221.9 KB
2021-12-10 04:13
四半期報告書-第17期第1四半期(令和3年8月1日-令和3年10月31日)
Japanese 169.3 KB
2021-10-28 03:39
内部統制報告書-第16期(令和2年8月1日-令和3年7月31日)
Japanese 22.5 KB
2021-10-28 03:39
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all StemRIM Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for StemRIM Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for StemRIM Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.